65 related articles for article (PubMed ID: 9355964)
1. Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo.
Beilharz MW; McDonald W; Watson MW; Heng J; McGeachie J; Lawson CM
J Interferon Cytokine Res; 1997 Oct; 17(10):625-30. PubMed ID: 9355964
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo.
Bosio E; Beilharz MW; Watson MW; Lawson CM
J Interferon Cytokine Res; 1999 Aug; 19(8):869-76. PubMed ID: 10476931
[TBL] [Abstract][Full Text] [Related]
3. STAT2-Dependent Immune Responses Ensure Host Survival despite the Presence of a Potent Viral Antagonist.
Le-Trilling VTK; Wohlgemuth K; Rückborn MU; Jagnjic A; Maaßen F; Timmer L; Katschinski B; Trilling M
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743368
[TBL] [Abstract][Full Text] [Related]
4. Low-dose oral use of interferon inhibits virally induced myocarditis.
Lawson CM; Beilharz MW
J Interferon Cytokine Res; 1999 Aug; 19(8):863-7. PubMed ID: 10476930
[TBL] [Abstract][Full Text] [Related]
5. The IFN regulatory factor 7-dependent type I IFN response is not essential for early resistance against murine cytomegalovirus infection.
Steinberg C; Eisenächer K; Gross O; Reindl W; Schmitz F; Ruland J; Krug A
Eur J Immunol; 2009 Apr; 39(4):1007-18. PubMed ID: 19283778
[TBL] [Abstract][Full Text] [Related]
6. Intraocular viral replication after systemic murine cytomegalovirus infection requires immunosuppression.
Gao EK; Yu XH; Lin CP; Zhang H; Kaplan HJ
Invest Ophthalmol Vis Sci; 1995 Oct; 36(11):2322-7. PubMed ID: 7558728
[TBL] [Abstract][Full Text] [Related]
7. Replication of murine cytomegalovirus in differentiated macrophages as a determinant of viral pathogenesis.
Hanson LK; Slater JS; Karabekian Z; Virgin HW; Biron CA; Ruzek MC; van Rooijen N; Ciavarra RP; Stenberg RM; Campbell AE
J Virol; 1999 Jul; 73(7):5970-80. PubMed ID: 10364349
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the production of murine cytomegalovirus and interferon in macrophages.
Yamaguchi T; Shinagawa Y; Pollard RB
J Gen Virol; 1988 Dec; 69 ( Pt 12)():2961-71. PubMed ID: 2462012
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical response to prophylactic Didox (N-3, 4 trihydroxybenzamide) treatment in murine cytomegalovirus-infected mice.
Go V; Tang-Feldman YJ; Lochhead SR; Lochhead GR; Yu CQ; Elford HL; Inayat MS; Oakley OR; Pomeroy C
Antivir Ther; 2011; 16(8):1277-86. PubMed ID: 22155909
[TBL] [Abstract][Full Text] [Related]
10. Synergy of type I interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection.
Bartlett EJ; Cull VS; Brekalo NL; Lenzo JC; James CM
Immunol Cell Biol; 2002 Oct; 80(5):425-35. PubMed ID: 12225378
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cells promote early CD8 T cell responses against cytomegalovirus.
Robbins SH; Bessou G; Cornillon A; Zucchini N; Rupp B; Ruzsics Z; Sacher T; Tomasello E; Vivier E; Koszinowski UH; Dalod M
PLoS Pathog; 2007 Aug; 3(8):e123. PubMed ID: 17722980
[TBL] [Abstract][Full Text] [Related]
12. Characterization of interferon induction in mice of resistant and susceptible strains during murine cytomegalovirus infection.
Allan JE; Shellam GR
J Gen Virol; 1985 May; 66 ( Pt 5)():1105-12. PubMed ID: 2582082
[TBL] [Abstract][Full Text] [Related]
13. Multifactorial protective mechanisms to limit viral replication in the lung of mice during primary murine cytomegalovirus infection.
Fernandez JA; Rodrigues EG; Tsuji M
Viral Immunol; 2000; 13(3):287-95. PubMed ID: 11016594
[TBL] [Abstract][Full Text] [Related]
14. [Reduning injection inhibits replication and proliferation of mouse cytomegalovirus and down-regulates the expressions of IFN-γ and IL-6 in mouse cytomegalovirus pneumonia].
Zuo L; Chen Y; Zhang W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Dec; 29(12):1242-4. PubMed ID: 24321064
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation of murine cytomegalovirus-induced myocarditis in mice treated with lipopolysaccharide and tumor necrosis factor.
Lenzo JC; Fairweather D; Shellam GR; Lawson CM
Cell Immunol; 2001 Oct; 213(1):52-61. PubMed ID: 11747356
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-10 repletion suppresses pro-inflammatory cytokines and decreases liver pathology without altering viral replication in murine cytomegalovirus (MCMV)-infected IL-10 knockout mice.
Tang-Feldman YJ; Lochhead GR; Lochhead SR; Yu C; Pomeroy C
Inflamm Res; 2011 Mar; 60(3):233-43. PubMed ID: 20922456
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the temperature-sensitive murine cytomegalovirus (MCMV) mutants tsm5 and tsm30: a study of genes involved in immune evasion, DNA packaging and processing, and DNA replication.
Sweet C; Ball K; Morley PJ; Guilfoyle K; Kirby M
J Med Virol; 2007 Mar; 79(3):285-99. PubMed ID: 17245727
[TBL] [Abstract][Full Text] [Related]
18. Control of murine cytomegalovirus replication in salivary glands during acute infection is independent of the Fas ligand/Fas system.
Riera L; Gariglio M; Pagano M; Gaiola O; Simon MM; Landolfo S
New Microbiol; 2001 Jul; 24(3):231-8. PubMed ID: 11497079
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activities of individual murine IFN-alpha subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication.
Yeow WS; Lawson CM; Beilharz MW
J Immunol; 1998 Mar; 160(6):2932-9. PubMed ID: 9510197
[TBL] [Abstract][Full Text] [Related]
20. The role of interferons in the resistance to murine cytomegalovirus.
Martinotti MG; Gariglio M; Cofano F; Cavallo G; Landolfo S
Microbiologica; 1990 Oct; 13(4):305-9. PubMed ID: 1708083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
